Loss of the m-AAA protease subunit AFG₃L₂ causes mitochondrial transport defects and tau hyperphosphorylation

Area of Science:

• Mitochondrial biology
• Neuroscience
• Molecular genetics

Background:

• AFG3L2, an m-AAA protease, is crucial for mitochondrial inner membrane substrate processing.
• Mutations in AFG3L2 cause spinocerebellar ataxia SCA28 and affect neuronal development and survival.
• Loss of AFG3L2 leads to mitochondrial network fragmentation, but the neurodegeneration mechanism remains unclear.

Purpose of the Study:

• To elucidate the pathogenic mechanism of neurodegeneration in AFG3L2-deficient neurons.
• To investigate the role of AFG3L2 in mitochondrial transport in the nervous system.
• To identify potential therapeutic targets for AFG3L2-associated neurodegenerative diseases.

Main Methods:

• Depletion of AFG3L2 in murine cortical neurons.
• Assessment of mitochondrial transport using live-cell imaging.
• Analysis of OPA1 processing and mitochondrial fusion.
• Treatment with antioxidants (N-acetylcysteine, vitamin E) and tau reduction strategies.
• Detection of tau hyperphosphorylation and ERK kinase activation.

Main Results:

• AFG3L2 depletion specifically impairs anterograde mitochondrial transport.
• Mitochondrial transport defects are independent of OPA1 processing and fusion.
• Antioxidant treatment and decreased tau levels rescue mitochondrial transport.
• Tau hyperphosphorylation and ERK kinase activation are observed in AFG3L2-deficient neurons.

Conclusions:

• Reactive oxygen species signaling contributes to cytoskeletal modifications that impair mitochondrial transport in AFG3L2-deficient neurons.
• Targeting oxidative stress and tau pathology may offer therapeutic strategies for AFG3L2-related neurodegeneration.
• This study reveals a novel mechanism linking AFG3L2 function, mitochondrial transport, and neurodegeneration.